Document is current
Any future updates will be listed below
-
Authors
Rashid, Narmeen S.
Lamba, Nayan
Catalano, Paul J.
Bi, Wenya Linda
Arnaout, Omar
Tanguturi, Shyam K.
Rahman, Rifaquat
Haas-Kogan, Daphne A.
Lin, Nancy U.
Wen, Patrick Y.
Aizer, Ayal A.
-
Funding
Funding for this research was provided by:
Office of Scholarly Engagement, Program in Medical Education, Harvard Medical School
- License Information
-
More Information
Article History
Received: 16 July 2024
Accepted: 6 September 2024
First Online: 5 October 2024
Declarations
:
: Rifaquat Rahman reports consulting fees from Servier Pharmaceuticals and Telix Pharmaceuticals. Patrick Y. Wen reports research support from Astra Zeneca, Black Diamond, Bristol Meyers Squibb, Chimerix, Eli Lily, Erasca, Global Coalition For Adaptive Research, Kazia, MediciNova, Merck, Novartis, Quadriga, Servier, and VBI Vaccines and advisory board/consulting activities for Anheart, Astra Zeneca, Black Diamond, Celularity, Chimerix, Day One Bio, Genenta, Glaxo Smith Kline, Kintara, Merck, Mundipharma, Novartis, Novocure, Prelude Therapeutics, Sagimet, Sapience, Servier, Symbio, Tango, Telix, VBI Vaccines. Ayal A. Aizer reports research funding from Varian and NH TheraAguix and consulting for Novartis and Seagen. All other authors report no relevant financial or non-financial interests.
: The institutional review board at our institution approved this study.
: A waiver of informed consent was obtained for this study.
: A waiver of informed consent was obtained for this study.
